Drugs that contain Ceftolozane Sulfate; Tazobactam Sodium

1. List of Zerbaxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7129232 CUBIST PHARMS LLC Cephem compounds
May, 2028

(5 years from now)

US8685957 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8476425 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8906898 CUBIST PHARMS LLC Solid forms of ceftolozane
May, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724353 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(9 years from now)

US10028963 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(9 years from now)

US11278622 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US8968753 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(11 years from now)

US10420841 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US9872906 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US9320740 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(11 years from now)

US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(11 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(11 years from now)

US10125149 CUBIST PHARMS LLC Synthesis of cephalosporin compounds
Aug, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2019
New Patient Population (NPP) Apr 21, 2025
Generating Antibiotic Incentives Now (GAIN) Dec 19, 2024

NCE-1 date: December, 2023

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hospital-acquired bacterial pneumonia; Treatment of ventilator-associated bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associated bacterial pneumonia (vabp); Treatment of complicated urinary tract infection, including pyelonephritis; Treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection; Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; Treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Methods of treating bacterial illnesses; Methods for treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in